stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Spyre Therapeutics, Inc.

United States 路 NASDAQ:聽SYRE 路 Market cap: 路 P/E: 路 P/S:

Spyre Therapeutics develops long-acting antibody drugs for inflammatory bowel diseases and rheumatic diseases.

Spyre Therapeutics is a drug developer building antibody medicines for people with inflammatory bowel diseases like ulcerative colitis and Crohn's disease, and for rheumatic diseases. Its pitch is simple: take biological drugs that are already known to work, and make them last much longer in the body. Instead of frequent infusions or injections, patients could get treatment far less often.

The science behind this is "half-life extension." Antibodies naturally get cleared from the body over time, so drugmakers tweak the molecule so it sticks around longer. Spyre licenses and engineers antibodies against well-validated immune targets, then combines them into combination therapies, betting that hitting several pathways at once works better than one drug alone. The company's most advanced programs are in inflammatory bowel disease, where it is running clinical trials; the rheumatic disease work is earlier stage. Spyre is a clinical-stage company, which means it has no approved products and no product revenue. It is funded by investors and by selling shares, and it burns cash on research and trials. The company went public in 2023 by merging with a listed shell company, raising money from investors including Fairmount Funds-backed vehicles and other specialist biotech funds. Its strategy of combining multiple antibodies is unusual in immunology, where most companies develop one drug at a time.


The big risks are the usual ones for early biotech: trials can fail, regulators can say no, and larger rivals are chasing the same immune targets. Success would likely come through partnerships or an acquisition by a bigger drugmaker, since Spyre has no salesforce or manufacturing scale of its own. For investors, it is a high-risk bet on whether longer-lasting, combination antibody drugs can beat today's standard treatments for chronic inflammatory disease.

Saved answer 路 last researched 16 Nov 2026